Trial Profile
Interventional, Randomized, Single-dose, Open-label, Crossover, Bioequivalence Study in Healthy Subjects to Compare Two Pharmaceutical Formulations of Memantine (Ebixa) in Fasted and Fed Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2019
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease; Cognition disorders; Dementia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 25 Jan 2019 Status changed from recruiting to completed.
- 20 Sep 2018 New trial record